Huawei – a leading global provider of information and communication technology

Huawei is a leading global provider of information and communication technology (ICT), infrastructure and smart devices. With integrated solutions for all four important areas – telecommunication networks, IT, smart devices and cloud services – we enable a fully networked world with clever functions for every single customer, in every apartment and in every company.

About the HUAWEI Consumer Business Group


As one of HUAWEI’s three business groups, the HUAWEI Consumer Business Group is a leader in all artificial intelligence (AI) scenarios. Smartphones, PCs, tablets, technology for families and cloud services are also offered. The HUAWEI Consumer Business Group has set itself the task of offering consumers the latest technology and sharing the joy of technological progress with people all over the world. We all go this way and make dreams come true.milestone2019Sep: HUAWEI presented the groundbreaking HUAWEI Mate 30 series at an exclusive event in Munich. With the Kirin 990 5G System on a Chip, a revolutionary 4-way camera and its unique HUAWEI Horizon display with OLED technology, the HUAWEI Mate 30 series sets new standards. And that in every category. Starting with the aesthetic design and the built-in hardware to software innovations – the HUAWEI Mate 30 series offers limitless possibilities.Sep: As part of the International Consumer Electronics Fair (IFA) 2019, HUAWEI presents its new smartphone chipsets with the Kirin 990 and Kirin 990 5G. The Kirin 990 5G is the world’s first commercially available 5G System on a Chip (SoC), which for the first time combines a CPU and 5G modem on one chip. The Kirin 990 5G thus gives end consumers special access to the outstanding 5G speed in the first year of the 5G and new mobile communications age.
August: HUAWEI presents its HarmonyOS at its in-house developer conference, the HUAWEI Developer Conference. The operating system based on microkernels is designed to offer a particularly intuitive user experience across all device classes and possible uses.
HarmonyOS is a compact and simply structured operating system with great performance potential. Initially, it will be used in smart devices such as smartwatches, smart displays and speakers as well as in vehicle systems. With this integration across all product classes, HUAWEI wants to create a networked ecosystem that is secure and resilient and enables a particularly simple user experience for all devices.
Jul: HUAWEI announces its business figures for the first half of 2019. The HUAWEI Consumer Business Group achieved sales of 220.8 billion Chinese yuan in the first half of the year.
The number of smartphones delivered (including Honor smartphones) amounts to 118 million devices, an increase of 24 percent compared to the same period last year. The company has also seen a large increase in the number of tablets, PCs and wearables shipped. HUAWEI begins to expand its device ecosystem with services. At this point, the HUAWEI Mobile Service Ecosystem has more than 800,000 registered developers and 500 million users around the world.
Jul: HUAWEI brings the world’s first 5G smartphone with dual-mode technology, the HUAWEI Mate 20 X 5G, to China after it premiered in Switzerland in May.
The HUAWEI Mate 20 X 5G is the first and to date the only commercially available 5G smartphone that supports dual-chip configuration using the HUAWEI Kirin 980 and Balong 5000. This means that standalone (SA) and non-standalone 5G networks (NSA) can be used. In addition, the HUAWEI Mate 20 X 5G will be the first 5G smartphone to have access to China’s 5G network in June.
Jul: After years of record-breaking growth, HUAWEI ranks 61st on the prestigious Fortune 500 list. That means a jump of eleven places compared to the previous year and a leap of an impressive 68 places since 2017.Jul: The HUAWEI Mate 20 X 5G – the world’s first 5G smartphone with dual mode technology – is the first smartphone ever to receive an award from the Global Certification Forum (GCF) because it is the first smartphone to pass all GCF 5G tests. Jun: In the “Top 100 Most Valuable Global Brands” study by BrandZ’s, HUAWEI ranks 47th. Compared to the previous year, the company made up one place and increased its brand value by eight percent. This is the fourth time in a row that HUAWEI is among the top 50 of the world’s most valuable brands.Apr: HUAWEI announces its business figures for the first quarter of 2019. The HUAWEI Consumer Business Group manages to create added value for consumers with innovative products. HUAWEI ships 59 million smartphones in the first quarter. In other areas such as PCs, wearables and smart home products, HUAWEI is valued by customers for its excellent products and first-class user experience.March: Huawei rewritten the rules of photography with the groundbreaking HUAWEI P30 series. The series contains the innovative HUAWEI SuperSpectrum sensor, an optical SuperZoom lens (5x optical zoom, 10x hybrid zoom and up to 50x digital zoom), a new HUAWEI ToF lens (Time of Flight) and the improved, optical AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro can take incredible photos and videos in any scenario.
Februar: Auf dem MWC 2019 präsentiert HUAWEI das HUAWEI Mate X, das schnellste faltbare 5G Smartphone der Welt. Das HUAWEI Mate X gewinnt die wichtigste Auszeichnung der Branche: GSMAs “Best New Connected Mobile Device at Mobile World Congress 2019”. Das HUAWEI Mate X verfügt über ein Falcon Wing Mechanical Hinge Design, ein 7nm Multimode-Modem (Kirin 980 + Balong 5000) und einen leistungsstarken 4.500 mAh-Akku und mit der weltweit schnellsten Ladetechnologie ausgestattet ist – 55W HUAWEI SuperCharge.
Huawei stellt auch das aktualisierte HUAWEI MateBook X Pro, das HUAWEI MateBook 13 und das HUAWEI MateBook 14 vor. Diese Produkte bieten den Nutzern eine hervorragende Hochgeschwindigkeits-Konnektivität und bringen ein komplett vernetztes Erlebnis näher als je zuvor.
Januar: Huawei präsentiert seinen 5G-Multimode-Chipsatz, den Balong 5000, und launcht das erste kommerzielle 5G-Gerät, den HUAWEI 5G CPE Pro.
Die neuen Produkte bieten dem Nutzer ein brandneues 5G-Erlebnis bei mehreren Anwendungsbereichen.
2018
Oktober: HUAWEI präsentiert die HUAWEI Mate 20-Serie mit dem Kirin 980, HUAWEISs leistungsstärksten System-on-a-Chip (SoC). Die Flaggschiff-Serie umfasst drei Geräte: HUAWEI Mate 20, HUAWEI Mate 20 Pro und PORSCHE DESIGN HUAWEI Mate 20 RS.
Das Kamerasystem der HUAWEI Mate 20-Serie beinhaltet ein Leica Ultra-Weitwinkelobjektiv mit dem Anwender nicht nur mehr von der Szenerie sehen können, auch Details auf sehr kurze Enternung sind scharf sichtbar dank der neuen Makro-Aufnahmefunktion.
Oktober: HUAWEI wird bei Best Global Brands 2018, veröffentlicht von Interbrand, auf Platz 68 der wertvollsten Marken gewählt. Seit 2017 kletterte HUAWEI um zwei Plätze nach oben. Der Markenwert stieg um 14 Prozent auf 7,6 Milliarden US-Dollar.
August: HUAWEI stellt den Kirin 980 vorgestellt, den weltweit ersten 7nm System-on-a-Chip für Mobiltelefone.
August: Nach IDC ist HUAWEI seit dem zweiten Quartal 2018 die weltweite Nummer zwei auf dem Smartphonemarkt.
Mai: Huawei ist das einzige chinesische Unternehmen, das 2018 in der jährlich von Forbes zusammengestellten Liste der wertvollsten Marken der Welt aufgeführt war – mit einem Markenwert von 8,4 Milliarden Dollar.
Mär: Huawei stellt die Smartphones der Serie HUAWEI P20 und Porsche Design HUAWEI Mate RS vor. HUAWEI P20 Pro erreicht bei DxOMark ein Ergebnis von 109 – das bis dato beste Ergebnis.
Feb: Huawei introduces the HUAWEI MateBook X Profi and the HUAWEI MediaPad M5 series
Further information


Products:
– Smartphone
– Wearables
– Equipment’s
– Smart Homes
– Mobile Services
– Emui 11.
– Huawei Store

For Full Information, You Can Vist!

%%footer%%

CRISPR and another genetic strategy fix cell defects in two common blood disorders

Victoria Gray (right), shown with researcher Haydar Frangoul, was the first patient to be treated with the gene-editing tool CRISPR for sickle cell disease. AMANDA STULTS/SARAH CANNON RESEARCH INSTITUTE/THE CHILDREN’S HOSPITAL AT TRISTAR CENTENNIAL
Dec. 5, 2020
It is a double milestone: new evidence that cures are possible for many people born with sickle cell disease and another serious blood disorder, beta-thalassemia, and a first for the genome editor CRISPR.
In today’s issue of The New England Journal of Medicine (NEJM) and tomorrow at the American Society of Hematology (ASH) meeting, teams report that two strategies for directly fixing malfunctioning blood cells have dramatically improved the health of a handful of people with these genetic diseases. One relies on CRISPR, marking the first inherited disease treated with the powerful tool created just 8 years ago. And both treatments are among a wave of genetic strategies poised to widely expand who can be freed of the two conditions. The only current cure, a bone marrow transplant, is risky, and appropriately matched donors are often scarce.
The novel genetic treatments still need longer folllow up, have the same safety issues as bone marrow transplants for now, and may also be extraordinarily expensive, but there is hope those risks can be eliminated and the costs pared down. “This is an amazing time, and it’s exciting because it’s happening all at once,” says hematologist Alexis Thompson of Northwestern University, who with a company called Bluebird Bio continues to test yet another genetic strategy that first demonstrated a sickle cell fix several years ago.
SIGN UP FOR OUR DAILY NEWSLETTER
Get more great content like this delivered right to you!
People born with sickle cell disease have mutations in their two copies of a gene for hemoglobin, the oxygen-carrying protein in red blood cells. The altered proteins stiffen normally flexible red blood cells into a sicklelike shape. The cells can clog blood vessels, triggering severe pain and raising the risk of organ damage and strokes. Sickle cell disease is among the most common inherited diseases, affecting 100,000 Black people in the United States alone. (The sickling mutations became widespread in African people, as one copy protects blood cells from malaria parasites.)
People with beta-thalassemia make little or no functioning hemoglobin, because of other mutations that affect the same subunit of the protein. About 60,000 babies are born each year globally with symptoms of the disease, largely of Mediterranean, Middle Eastern, and South Asian ancestry. Blood transfusions are standard treatment for both diseases, relieving the severe anemia they can cause, and drugs can somewhat reduce the debilitating “crises” that often send sickle cell patients to the hospital.
In the two new treatments, investigators have tinkered with genes to counter the malfunctioning hemoglobin. They remove a patient’s blood stem cells and, in the lab, disable a genetic switch called BCL11A that, early in life, shuts off the gene for a fetal form of hemoglobin. The patient then receives chemotherapy to wipe out their diseased cells, and the altered stem cells are infused. With the fetal gene now active, the fetal protein restores missing hemoglobin in thalassemia. In sickle cell disease it replaces some of the flawed adult sickling hemoglobin, and also blocks any remaining from forming sticky polymers.
“It’s enough to dilute the effect,” says Samarth Kulkarni, CEO of CRISPR Therapeutics, which partnered with Vertex Pharmaceuticals on using the genome editor.
They engineered CRISPR’s DNA-cutting enzyme and “guide RNA” to home in on and break the BCL11A gene. In a more traditional gene therapy effort, a team led by gene therapy researcher David Williams of Boston Children’s Hospital achieved the same goal. They used a harmless virus to paste into the blood stem cells’ genome a stretch of DNA coding for a strand of RNA that silences the fetal hemoglobin off switch.
Patients treated in both trials have begun to make sufficiently high levels of fetal hemoglobin and no longer have sickle cell crises or, in all but a single case, a need for transfusions. In one NEJM paper today, the Boston Children’s team reports on the success of its virus gene therapy in six sickle cell patients treated for at least 6 months. They include a teenager who can now go swimming without pain, and a young man who once needed transfusions but has gone without them nearly 2.5 years, says Erica Esrick of Boston Children’s. “He feels perfectly normal.”
CRISPR appears to have done at least as well. The first sickle cell patient to receive CRISPR 17 months ago, a Mississippi mother of four named Victoria Gray, has called the results “wonderful.” “We have ameliorated the symptoms,” says Haydar Frangoul, a hematologist at the Sarah Cannon Research Institute who treated Gray as part of the CRISPR trial. “Every time I call her on the phone or see her in the clinic, she feels great.”
CRISPR Therapeutics and Vertex describe the results for Gray and one beta-thalassemia patient treated 22 months ago today in another NEJM paper, and Frangoul will report on seven beta-thalassemia and three sickle cell patients tomorrow at the online ASH meeting. The CRISPR results “are really very impressive,” says Boston Children’s stem cell biologist Stuart Orkin, whose lab discovered the BCL11A switch that led to both trials. (He is not directly involved with either.)
The results are comparable to the older strategy from Bluebird that relies on a different genetic alteration: adding a gene for an adult hemoglobin that has been tweaked so it reduces polymerization of the sickling form. At the ASH meeting, Thompson will give an update on about two dozen sickle cell disease patients who received the treatment within the past 3 years. As of March, the 14 with a follow-up of 6 months or more had experienced just a single mild pain crisis overall.
The Bluebird treatment was approved in Europe in 2019 for certain beta-thalassemia patients, and the company expects to seek Food and Drug Administration approval in the United States for its products for both diseases within the next few years. Bluebird chief scientific officer Philip Gregory says the long-term data for the firm’s treatment give it an advantage over the newer approaches. “We’ve set a very high bar,” he says.
Others who treat these diseases say it’s too early to crown a specific genetic treatment the winner. For example, reversing the fetal hemoglobin off switch, as the new CRISPR and RNA-based gene therapy strategies do, allows blood cells to make natural levels of the protein. But so far there are no signs that Bluebird’s treatment results in excess adult hemoglobin that causes problems, Williams says. And although a virus-carrying gene can land in the wrong place and trigger cancer, CRISPR could similarly make harmful off-target edits. There has been no sign of that. Still, “We need long-term follow-up” for all the strategies, says the National Institutes of Health’s (NIH’s) John Tisdale, a coleader of the Bluebird study.
None of these genetic treatments seems likely to immediately help the many patients in places like Africa and India who don’t have access to sophisticated health care. “It’s wonderful, but it won’t solve the global health problem,” Orkin says. Bluebird expects to charge $1.8 million for LentiGlobin in Europe—a sum it derived from looking at a patient’s gains in life span and quality of life—and the other genetic treatments are likely to be similarly expensive. Costs will also include the chemotherapy needed to eliminate patients diseased blood stem cells, and the attendant hospital stay.
Bluebird and other groups are exploring whether antibodies, instead of harsh chemotherapy, can wipe out a patient’s diseased cells. In a bolder effort, NIH and the Bill & Melinda Gates Foundation last year announced a plan to put at least $100 million into developing technologies that would modify blood stem cells in a patient’s bone marrow by injecting the gene-editing tools themselves into the body. “It’s a big hairy goal, but it’s an engineering challenge,” says gene therapy researcher Donald Kohn of the University of California, Los Angeles, who leads another sickle cell treatment trial. “We’ll get there.”

For Full Information, You Can Visit!

 

 

Home For Sale – Stunning 2 level penthouse at Texan Tower, Just 4 blocks from UT.

Stunning 2 level penthouse at Texan Tower, Just 4 blocks from UT.

Main level has 2 bedrooms; 3rd bed/loft upstairs. Private balcony with incredible western views Unit is ultra-private with only one common wall with no neighbors above. Upgrades include: Quartz countertops throughout; upgraded baths & kitchen with newer appliances/hardware Rooftop pool, 2 parking spaces underground garage leased thru 7/31/2021 @ $2,195/mo.

For Full Information, You Can Visit!

 

35 Stylish Garden Ideas That Will Make You Feel More Relaxed – Engineering Discoveries

The front yard of your home is the first impression people get, so you really want it to look good. There are a lot of different options for landscaping your front yard: an extremely manicured garden, a minimal approach, or a natural appeal. The great news is that a lot of these front yard landscaping ideas can be done just as well on a budget. Let’s check out some great ideas to create a beautiful and welcoming front yard.

For Full Information, You Can Visit!

 

 

Economics – U.S. Jobless Claims Drop, Offering Ray of Hope for Labor Market

Updated on 3 December 2020, 15:37 CET
• Benefits applications remain well above pre-pandemic levels
• Further improvement threatened by surge in coronavirus cases
A worker installs plumbing at the HL Enterprise manufacturing facility in Elkhart, Indiana. Photographer: Ty Wright/Bloomberg
Applications for U.S. state unemployment benefits fell by the most in almost two months, offering some hope that the gradual recovery in the job market will continue despite a spike in Covid-19 infections and renewed business restrictions.
Initial jobless claims in regular state programs decreased by 75,000 to 712,000 in the week ended Nov. 28, the first drop in three weeks, Labor Department data showed Thursday. Without adjustments for seasonal fluctuations, applications dropped by about 122,000 during the period.
Follow reaction in real time here on Bloomberg’s TOPLive blog
Continuing claims — the total pool of Americans on state unemployment benefits — declined 569,000 to 5.52 million in the week ended Nov. 21.

The main figures were below economists’ projections for 775,000 initial claims and 5.8 million continuing claims, based on the median estimates in Bloomberg surveys. One caveat: seasonal adjustments on claims data tend to be trickier around holidays, and last week included Thanksgiving, making it important to see if the trend holds.
While the latest claims figures show gradual improvement, they’re still well above pre-pandemic levels. The labor market also remains challenged by a rising number of Covid-19 cases and a tightening of business restrictions in parts of the U.S. Some industries such as travel, leisure and hospitality are still depressed by the pandemic and could cut jobs more aggressively in the absence of additional fiscal relief.
The data show a labor market that “continues to progress through the pandemic, but still has a long road to a complete recovery,” Ian Lyngen, head of U.S. rates strategy at BMO Capital Markets, said in a note.
U.S. stocks were little changed at the open, while 10-year Treasury yields fell along with the dollar.
All but 10 states and territories posted unadjusted declines in initial claims last week, with some of the biggest drops occurring in California, Texas, Michigan and Georgia. Illinois, Oregon and Indiana reported the largest increases in filings during the holiday week.
Adjustment Issues
“The plunge in initial claims does not refute the idea that the trend is rising; we expected a sharp fall because of the difficulty of adjusting for Thanksgiving,” Ian Shepherdson, chief economist at Pantheon Macroeconomics, wrote in a note. He had forecast claims of 725,000.
The government’s monthly jobs report on Friday is projected to show payrolls grew by about 475,000 in November, still solid yet the smallest gain in seven months, according to the median forecast in a Bloomberg survey of economists. The jobless rate is forecast to tick down to 6.8% from 6.9%.
A report on Wednesday from ADP Research Institute showed that companies in the U.S. added fewer jobs than expected in November, a sign that businesses are slowing down the rate of hiring as coronavirus cases reach new levels.
Continuing claims for Pandemic Unemployment Assistance, a program that provides benefits to self-employed and gig workers, decreased about 339,000 to 8.87 million in the week ended Nov. 14. This number, though, is inflated by multiple-counting and fraud, according to a government watchdog’s report this week, and the Labor Department plans to add a disclaimer.
More people have moved into extended programs like Pandemic Emergency Unemployment Compensation, but these were put in place by the Cares Act will expire by year-end and leave millions of people without government aid. The number of Americans on PEUC assistance rose slightly to 4.57 million in the week ended Nov. 14.
— With assistance by Chris Middleton, Jeff Kearns, Edith Moy, Sophie Caronello, Ye Xie, and Ana Monteiro
(Updates with market open, adds analyst comment)

For Full Information, You Can Visit!

 

UK Authorizes Pfizer Coronavirus Vaccine For Emergency Use

British officials authorized a COVID-19 vaccine for emergency use on Wednesday, greenlighting the world’s first shot against the virus that’s backed by rigorous science and taking a major step toward eventually ending the pandemic.
The go-ahead for the vaccine developed by American drugmaker Pfizer and Germany’s BioNTech comes as the virus surges again in the United States and Europe, putting pressure on hospitals and morgues in some places and forcing new rounds of restrictions that have devastated economies.
The Medicines and Healthcare Products Regulatory Agency, which licenses drugs in the U.K., recommended the vaccine could be used after it reviewed the results of clinical trials that showed the vaccine was 95% effective overall — and that it also offered significant protection for older people, among those most at risk of dying from the disease. But the vaccine remains experimental while final testing is done.

“Help is on its way,″ British Health Secretary Matt Hancock told the BBC, adding that the situation would start to improve in the spring.
“We now have a vaccine. We’re the first country in the world to have one formally clinically authorized but, between now and then, we’ve got to hold on, we’ve got to hold our resolve,” he said.
MORE ON THE PANDEMIC
Other countries aren’t far behind: Regulators in the United States and the European Union also are vetting the Pfizer shot along with a similar vaccine made by competitor Moderna Inc. British regulators also are considering another shot made by AstraZeneca and Oxford University.
Hancock said Britain expects to begin receiving the first shipment of 800,000 doses “within days,″ and people will begin receiving shots as soon as the National Health Service gets the vaccine.
Doses everywhere are scarce, and initial supplies will be rationed until more is manufactured in the first several months of next year.
A government committee will release details of vaccination priorities later Wednesday, but Hancock said nursing home residents, people over 80, and healthcare workers and other care workers will be the first to receive the shot.
Pfizer said it would immediately begin shipping limited supplies to the U.K. — and has been gearing up for even wider distribution if given a jsimilar nod by the U.S. Food and Drug Administration, a decision expected as early as next week.
Pfizer CEO Albert Bourla called the U.K. decision “a historic moment.”
“We are focusing on moving with the same level of urgency to safely supply a high-quality vaccine around the world,” Bourla said in a statement.

While the U.K. has ordered 40 million doses of the Pfizer vaccine, enough for 20 million people, it’s not clear how many will arrive by year’s end. Hancock said the U.K. expects to receive “millions of doses” by the end of this year, adding that the actual number will depend on how fast Pfizer can produce the vaccine.
One concern about the Pfizer-BioNTech vaccine is that it must be stored and shipped at ultra-cold temperatures of around minus 70 degrees Celsius (minus 94 degrees Fahrenheit), adding to the challenge of distributing the vaccine around the world.
Pfizer says it has developed shipping containers that use dry ice to keep the vaccine cool. GPS-enabled sensors will allow the company to track each shipment and ensure they stay cold, the company says.
“Pfizer has vast experience and expertise in cold-chain shipping and has an established infrastructure to supply the vaccine worldwide, including distribution hubs that can store vaccine doses for up to six months,” the company said in a statement.
The company also says it has agreed to work with other vaccine makers to ensure there is sufficient supply and a range of vaccines, “including those suitable for global access.”
Every country has different rules for determining when an experimental vaccine is safe and effective enough to use. Intense political pressure to be the first to roll out a rigorously scientifically tested shot colored the race in the U.S. and Britain, even as researchers pledged to cut no corners. In contrast, China and Russia have offered different vaccinations to their citizens ahead of late-stage testing.
The shots made by U.S.-based Pfizer and its German partner BioNTech were tested in tens of thousands of people. And while that study isn’t complete, early results suggest the vaccine is 95% effective at preventing mild to severe COVID-19 disease. The companies told regulators that of the first 170 infections detected in study volunteers, only eight were among people who’d received the actual vaccine and the rest had gotten a dummy shot.
ADVERTISEMENT
“This is an extraordinarily strong protection,” Dr. Ugur Sahin, BioNTech’s CEO, recently told The Associated Press.
The companies also reported no serious side effects, although vaccine recipients may experience temporary pain and flu-like reactions immediately after injections.
Final testing must still be completed. Still to be determined is whether the Pfizer-BioNTech shots protect against people spreading the coronavirus without showing symptoms. Another question is how long protection lasts.
The vaccine also has been tested in only a small number of children, none younger than 12, and there’s no information on its effects in pregnant women.

For Full Information, You Can Visit!

 

About Data Sonification – A New Cosmic Triad of Sound

A new trio of examples of ‘data sonification’ from NASA missions provides a new method to enjoy an arrangement of cosmic objects. Data sonification translates information collected by various NASA missions — such as the Chandra X-ray Observatory, Hubble Space Telescope, and Spitzer Space Telescope — into sounds.
This image of the Bullet Cluster (officially known as 1E 0657-56) provided the first direct proof of dark matter, the mysterious unseen substance that makes up the vast majority of matter in the Universe. X-rays from Chandra (pink) show where the hot gas in two merging galaxy clusters has been wrenched away from dark matter, seen through a process known as “gravitational lensing” in data from Hubble (blue) and ground-based telescopes. In converting this into sound, the data pan left to right, and each layer of data was limited to a specific frequency range. Data showing dark matter are represented by the lowest frequencies, while X-rays are assigned to the highest frequencies. The galaxies in the image revealed by Hubble data, many of which are in the cluster, are in mid-range frequencies. Then, within each layer, the pitch is set to increase from the bottom of the image to the top so that objects towards the top produce higher tones.
This image of the Bullet Cluster (officially known as 1E 0657-56) provided the first direct proof of dark matter, the mysterious unseen substance that makes up the vast majority of matter in the Universe. X-rays from Chandra (pink) show where the hot gas in two merging galaxy clusters has been wrenched away from dark matter, seen through a process known as “gravitational lensing” in data from Hubble Space Telescope (blue) and ground-based telescopes. In converting this into sound, the data pan left to right, and each layer of data was limited to a specific frequency range. Data showing dark matter are represented by the lowest frequencies, while X-rays are assigned to the highest frequencies. The galaxies in the image revealed by Hubble data, many of which are in the cluster, are in mid-range frequencies. Then, within each layer, the pitch is set to increase from the bottom of the image to the top so that objects towards the top produce higher tones.
Credits: NASA/CXC/SAO/K.Arcand, SYSTEM Sounds (M. Russo, A. Santaguida)
The Crab Nebula has been studied by people since it first appeared in Earth’s sky in 1054 A.D. Modern telescopes have captured its enduring engine powered by a quickly spinning neutron star that formed when a massive star collapsed. The combination of rapid rotation and a strong magnetic field generates jets of matter and anti-matter flowing away from its poles, and winds outward from its equator. For the translation of these data into sound, which also pans left to right, each wavelength of light has been paired with a different family of instruments. X-rays from Chandra (blue and white) are brass, optical light data from Hubble (purple) are strings, and infrared data from Spitzer (pink) can be heard in the woodwinds. In each case, light received towards the top of the image is played as higher pitched notes and brighter light is played louder.
The Crab Nebula has been studied by people since it first appeared in Earth’s sky in 1054 A.D. Modern telescopes have captured its enduring engine powered by a quickly spinning neutron star that formed when a massive star collapsed. The combination of rapid rotation and a strong magnetic field generates jets of matter and anti-matter flowing away from its poles, and winds outward from its equator. For the translation of these data into sound, which also pans left to right, each wavelength of light has been paired with a different family of instruments. X-rays from Chandra X-ray Observatory (blue and white) are brass, optical light data from Hubble Space Telescope (purple) are strings, and infrared data from Spitzer (pink) can be heard in the woodwinds. In each case, light received towards the top of the image is played as higher pitched notes and brighter light is played louder.
Credits: NASA/CXC/SAO/K.Arcand, SYSTEM Sounds (M. Russo, A. Santaguida)
On February 24, 1987, observers in the southern hemisphere saw a new object in the Large Magellanic Cloud, a small satellite galaxy to the Milky Way. This was one of the brightest supernova explosions in centuries and soon became known as Supernova 1987A (SN 87A). This time lapse shows a series of Chandra (blue) and Hubble (orange and red) observations taken between 1999 and 2013. This shows a dense ring of gas, which was ejected by the star before it went supernova, begins to glow brighter as the supernova shockwave passes through. As the focus sweeps around the image, the data are converted into the sound of a crystal singing bowl, with brighter light being heard as higher and louder notes. The optical data are converted to a higher range of notes than the X-ray data so both wavelengths of light can be heard simultaneously. An interactive version lets the user play this astronomical instrument for themselves.
On February 24, 1987, observers in the southern hemisphere saw a new object in the Large Magellanic Cloud, a small satellite galaxy to the Milky Way. This was one of the brightest supernova explosions in centuries and soon became known as Supernova 1987A (SN 87A). This time lapse shows a series of Chandra X-ray Observatory (blue) and Hubble Space Telescope (orange and red) observations taken between 1999 and 2013. This shows a dense ring of gas, which was ejected by the star before it went supernova, begins to glow brighter as the supernova shockwave passes through. As the focus sweeps around the image, the data are converted into the sound of a crystal singing bowl, with brighter light being heard as higher and louder notes. The optical data are converted to a higher range of notes than the X-ray data so both wavelengths of light can be heard simultaneously.
Credits: NASA/CXC/SAO/K.Arcand, SYSTEM Sounds (M. Russo, A. Santaguida)
The data sonification project is led by the Chandra X-ray Center (CXC) as part of the NASA’s Universe of Learning (UoL) program. NASA’s Science Activation program strives to enable NASA science experts and to incorporate NASA science content into the learning environment effectively and efficiently for learners of all ages. The collaboration was driven by visualization scientist Kimberly Arcand (CXC), astrophysicist Matt Russo and musician Andrew Santaguida (both of the SYSTEMS Sound project.)
NASA’s Marshall Space Flight Center manages the Chandra program. The Smithsonian Astrophysical Observatory’s Chandra X-ray Center controls science from Cambridge Massachusetts and flight operations from Burlington, Massachusetts. NASA’s Universe of Learning materials are based upon work supported by NASA under cooperative agreement award number NNX16AC65A to the Space Telescope Science Institute, working in partnership with Caltech/IPAC, Center for Astrophysics | Harvard & Smithsonian, Jet Propulsion Laboratory, and Sonoma State University.

For Full Information, You Can Visit!

 

By George Soros – An Effective Response to Europe’s Fiscal Paralysis

With Hungary and Poland vetoing the European Union’s budget and COVID-19 recovery fund, the case for issuing perpetual bonds has never been stronger. While the EU cannot currently do so, given uncertainty about its future, many of its member states can and should.
NEW YORK – I have written a lot in the past about the desirability of the European Union issuing perpetual bonds. But today I am proposing that individual member states should do so.
Right now, it would be impossible for the EU to issue perpetual bonds, because the member states are too divided. Poland and Hungary have vetoed the next EU budget and the COVID-19 recovery fund, and the so-called Frugal Five (Austria, Denmark, Germany, the Netherlands, and Sweden) are more interested in saving money than in contributing to the common good. Investors will buy perpetual bonds only from an entity that they believe will continue to exist for the foreseeable future. That was true of Britain in the eighteenth century (when it issued Consols) and of the United States in the nineteenth century (when it consolidated individual states’ debt). Sadly, it is not true of the EU today.
The EU finds itself in a very difficult situation. It is experiencing a second wave of COVID-19 that threatens to be even more devastating than the first. Member states used up most of their financial resources fighting the first wave. Providing health care and resuscitating the economy will require much more than the €1.8 trillion ($2.2 trillion) in the new budget and recovery fund, called Next Generation EU. In any case, the availability of those funds has been delayed by Hungary and Poland’s veto.
Hungarian Prime Minister Viktor Orbán is concerned that the EU’s new rule-of-law provision would impose practical limits on his personal and political corruption. He is so worried that he has concluded a binding cooperation agreement with Poland, dragging that country down with him.
It turns out that there is an easy way to overcome the veto: employ the so-called enhanced cooperation procedure. It was formalized in the Lisbon Treaty with the express purpose of creating a legal basis for further eurozone integration, but it was never used for that purpose. Its great merit is that it can be used for fiscal purposes. A sub-group of member states can set a budget and agree on a way to fund it – say, through a joint bond.
At this point, perpetual bonds could come in very useful. They would be issued by member states whose continued existence would be readily accepted by long-term investors such as life-insurance companies.
Subscribe to Project Syndicate
Enjoy unlimited access to the ideas and opinions of the world’s leading thinkers, including weekly long reads, book reviews, and interviews; The Year Ahead annual print magazine; the complete PS archive; and more – All for less than $9 a month.
SUBSCRIBE NOW
Perpetual bonds offer the great advantage that the principal never has to be repaid; only the annual interest is due. The discounted present value of future interest payments diminishes over time – it will approach, but never reach, zero. A certain amount of financial resources – say, the €1.8 trillion currently planned – would go several times further if it were used to issue perpetual bonds rather than ordinary bonds. This would largely solve Europe’s financial problems.
If one country issued perpetual bonds, it would have the additional advantage that other European countries would find it an example worth following. The Frugal Five should find perpetual bonds particularly attractive. After all, they like to save money.
There is a lot of unsatisfied demand in Europe from insurance companies and other long-term investors for long-term bonds. At first, they may demand a premium for perpetual bonds because they are not familiar with the instrument. But the premium is likely to disappear as they acquaint themselves with it.
Italy is not among the countries fortunate enough to be able to issue perpetual bonds in their own name; yet it needs the benefits more than others. Italy is the EU’s third largest economy – what would the EU be without it?

For Full Information, You Can Visit!

 

Tracking the Reopening of New York City – What You Need To Know

After months in an economically devastating lockdown, America’s largest metropolis is taking its first steps in the long slog back to normal. New York City, hobbled by what was once the biggest and deadliest Covid-19 outbreak in the country, began reopening on June 8, despite lingering concerns about the virus and against a backdrop of civil unrest over police brutality that led to protests, and at times, looting and violence.
Yet as the city’s economic engine revs up, questions abound: What will business in post-Covid New York look like? How will commuters manage in a social-distancing world? How will New York’s major industries, from finance to real estate and the arts, meet the needs of their customers and employees, all while trying to keep everyone safe?
Key Coverage
• NYC’s Virus Threat Has Faded, But Its Future Is Stuck in Limbo
• New York City Reopening Splits Along Lines of Wealth and Race
• New Yorkers Anxiously Exit Covid Lockdowns After 80 Days of Hell
By The Numbers
• $1.8TSize of New York metro area’s economy, which rivals that of many countries, including Brazil, Canada and South Korea
• 63MVisitors to New York City annually before the pandemic hit
• 900,000Jobs that the city may lose during lockdown
Why It Matters
No city is more important to America’s economic recovery than New York.
As the capital of American capitalism, it’s a global hub for business and commerce. The economic output of the New York metro area, estimated at $1.8 trillion, rivals that of entire nations. The city of 8.6 million is also the country’s center for banking and finance, real estate, media, retail, advertising, tourism and the arts.
100K New York Businesses Will ‘Disappear’: Bankruptcy Lawyer
100K New York Businesses Will ‘Disappear’: Bankruptcy Lawyer
Dozens of the world’s biggest companies are headquartered in New York City, employing hundreds of thousands of people across America and the world. It’s also home to Wall Street, a vital part of the city’s economy and the go-to destination for global capital.
So understanding how New York City emerges from the pandemic — through the lens of business and finance — is crucial to understanding the prospects of the U.S. economy as a whole.

For Full Information, You Can Visit!

 

Multi-Dimension Monitoring – The Software Is Real-Time Capable And Reacts Self-adaptively

flexis Multi Dimension Monitoring visualizes the supply situation and provides reliable transparency of bottlenecks, ranges of coverage, and inventories. This SCM software enables an objective, forward-looking identification of problems before they become critical and can even network different hierarchies. The program includes deviation management and transmits all information in real-time.
Outcome
A guaranteed ability to deliver while simultaneously reducing inventories. As a result, productivity increases considerably.
Benefit
The software is real-time capable and reacts self-adaptively, even when changes occur.

Detail Description
With the flexis Monitoring Solution, users can monitor processes in a global environment. For example, the software recognizes critical parts with long supply chains; it creates comprehensive transparency for requirements, inventories, and transports for the entire planning period. Using the alert function, supply risks or bottleneck situations are detected early, allowing immediate measures to be taken.
The program monitors the supply of parts in the short-term horizon against the planned sequence and compares inventories, shipments, and production. Parts that are responsible for bottleneck situations are defined. The program provides an overview of the saved stocks for planned production and filters the orders that are affected by a parts bottleneck.
The program checks the ability to deliver and identifies which requirements are covered and which cannot be met. It creates Shop FloorTransparency for the planner and displays the status of the products in the process in a clear and concise manner. The SCM system automatically sifts through planning alternatives.
Added Value
• Decisions can be made with real-time knowledge with “turbo transparency”
• Linked knowledge: holistic view of production, warehouse, and transport
• Secure basis for decision-making with a controlling rather than a reactive role
• Early detection of imminent bottlenecks through alarm functions
• Clear presentation like critical parts or critical orders

For Full Information, You Can Visit!